PTX 9908

Drug Profile

PTX 9908

Alternative Names: PTX-9908

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pertinax Therapeutics
  • Class Antineoplastics; CXC chemokines; Peptides
  • Mechanism of Action CXCR4 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer

Most Recent Events

  • 26 Feb 2016 Phase-I/II development is ongoing in North America
  • 09 Sep 2013 Pertinax Therapeutics and MicroConstants China enter into a licensing and development agreement for Hepatocellular carcinoma in China
  • 09 Sep 2013 Phase-I/II clinical trials in Cancer (in healthy volunteers and patients) in North America (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top